Harbour BioMed announced its wholly owned subsidiary has exercised a warrant agreement to acquire common stock in Spruce Biosciences. As a result of the transaction, Harbour BioMed holds approximately 3.8% of Spruce’s total outstanding shares (3.1% of fully diluted shares of Spruce). Harbour BioMed’s current focus is the discovery and development of novel antibody therapeutics in immunology and oncology. Background on Stock Agreement Previously, the warrant had been issued to the wholly...